ArticleTissue engineering. Part A2019
Aligned Nanofibrillar Scaffolds for Controlled Delivery of Modified mRNA.
Article in Tissue engineering. Part A, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- A mouse model of volumetric muscle loss and therapeutic scaffold implantation.Nature protocols · 2025Review
- Recent advances in gradient biomimetic scaffolds for tendon-bone interface regeneration.Frontiers in bioengineering and biotechnology · 2025Review
- Elastin-like protein hydrogels with controllable stress relaxation rate and stiffness modulate endothelial cell function.Journal of biomedical materials research. Part A · 2023Article
- Modified mRNA as a Treatment for Myocardial Infarction.International journal of molecular sciences · 2023Review
- Matrices Activated with Messenger RNA.Journal of functional biomaterials · 2023Review
- m6A methylation: Critical roles in aging and neurological diseases.Frontiers in molecular neuroscience · 2023Review
- Gelatin Nanoparticles for Complexation and Enhanced Cellular Delivery of mRNA.Nanomaterials (Basel, Switzerland) · 2022Article
- Cells, scaffolds, and bioactive factors: Engineering strategies for improving regeneration following volumetric muscle loss.Biomaterials · 2021Review
- RNA methylation and neurovascular unit remodeling.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2021Article
- Boost Tendon/Ligament Repair With Biomimetic and Smart Cellular Constructs.Frontiers in bioengineering and biotechnology · 2021Review
- Skeletal Muscle Tissue Engineering: Biomaterials-Based Strategies for the Treatment of Volumetric Muscle Loss.Bioengineering (Basel, Switzerland) · 2020Review
- Delivery of hepatocyte growth factor mRNA from nanofibrillar scaffolds in a pig model of peripheral arterial disease.Regenerative medicine · 2020Article
- The ins and outs of engineering functional tissues and organs: evaluating the in-vitro and in-situ processes.Current opinion in organ transplantation · 2019Review
- Engineering Biomimetic Materials for Skeletal Muscle Repair and Regeneration.Advanced healthcare materials · 2019Review
- Vascularization of Engineered Spatially Patterned Myocardial Tissue Derived From Human Pluripotent Stem CellsFrontiers in bioengineering and biotechnology · 2019Article
- Scaffold-mediated delivery for non-viral mRNA vaccines.Gene therapy · 2018Article
- Rehabilitative exercise and spatially patterned nanofibrillar scaffolds enhance vascularization and innervation following volumetric muscle loss.NPJ Regenerative medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
RNA-based vector delivery is a promising gene therapy approach. Recent advances in chemical modification of mRNA structure to form modified mRNA (mmRNA or cmRNA or modRNA) have substantially improved their stability and translational efficiency within cells. However, mmRNA conventionally delivered in solution can be taken up nonspecifically or become cleared away prematurely, which markedly limits the potential benefit of mmRNA therapy. To address this limitation, we developed mmRNA-incorporated nanofibrillar scaffolds that could target spatially localized delivery and temporally controlled release of the mmRNA both in vitro and in vivo. To establish the efficacy of mmRNA therapy, mmRNA encoding reporter proteins such as green fluorescence protein or firefly luciferase (Fluc) was loaded into aligned nanofibrillar collagen scaffolds. The mmRNA was released from mmRNA-loaded scaffolds in a transient and temporally controlled manner and induced transfection of human fibroblasts in a dose-dependent manner. In vitro transfection was further verified using mmRNA encoding the angiogenic growth factor, hepatocyte growth factor (HGF). Finally, scaffold-based delivery of HGF mmRNA to the site of surgically induced muscle injury in mice resulted in significantly higher vascular regeneration after 14 days, compared to implantation of Fluc mmRNA-releasing scaffolds. After transfection with Fluc mmRNA-releasing scaffold in vivo, Fluc activity was detectable and localized to the muscle region, based on noninvasive bioluminescence imaging. Scaffold-based local mmRNA delivery as an off-the-shelf form of gene therapy has broad translatability for treating a wide range of diseases or injuries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.